Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbromal SCHEMBL13723954 | 0.81 | HTT (0.32) | HTT | |
| SCHEMBL11411566 | 0.80 | — | — | |
| Bromisovalum SCHEMBL6723826 | 0.76 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3652416 | 0.75 | CRBN (0.43) | CRBNRECQLALDH1A1MEN1LMNA | |
| SCHEMBL9428999 | 0.74 | — | — | |
| SCHEMBL28728166 | 0.73 | DPP4 (0.48) | CRBNRECQLALDH1A1MEN1LMNA | |
| SCHEMBL10575445 | 0.73 | CRBN (0.42) | CRBNRECQLALDH1A1MEN1LMNA | |
| SCHEMBL28728167 | 0.73 | DPP4 (0.48) | CRBNRECQLALDH1A1MEN1LMNA | |
| SCHEMBL23691240 | 0.72 | — | — | |
| SCHEMBL4411230 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398855-A1 | BROMIDE SOURCE FOR USE IN TREATING AUTISM SPECTRAL DISORDER | INST NAT SANTE RECH MED (FR) | 2024-12-05 | — | — | US | claimed |
| US-12036237-B2 | Bromide source for use in treating autism spectral disorder | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2024-07-16 | — | — | US | claimed |
| US-20230256009-A1 | BROMIDE SOURCE FOR USE IN TREATING AUTISM SPECTRAL DISORDER | INSERM, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2023-08-17 | — | — | US | claimed |
| US-11666599-B2 | Bromide source for use in treating autism spectral disorder | INSERM, INTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2023-06-06 | — | — | US | claimed |
| US-20220273600-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-09-01 | — | — | US | claimed |
| US-20210106613-A1 | BROMIDE SOURCE FOR USE IN TREATING AUTISM SPECTRAL DISORDER | INRA, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2021-04-15 | — | — | US | claimed |
| EP-3651759-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | Syneurx International (Taiwan) Corp. (TW) | 2020-05-20 | — | — | EP | claimed |
| EP-3544599-A1 | BROMIDE SOURCE FOR USE IN TREATING AUTISM SPECTRAL DISORDER | (INSERM) Institut National de la Santé et de la Recherche Médicale (FR) | 2019-10-02 | — | — | EP | claimed |
| CN-110204460-A | A kind of bromisoval fabrication processing | 华润双鹤利民药业（济南）有限公司 | 2019-09-06 | — | — | CN | claimed |
| US-10226442-B2 | Lithium salts of N-substituted glycine compounds and uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2019-03-12 | — | — | US | claimed |
| EP-0729748-A1 | PROCESS FOR PRODUCING STABLE MEDICINAL COMPOSITION, AND PHARMACEUTICAL PREPARATION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1996-09-04 | — | — | EP | claimed |
| US-5374608-A | Compositions containing adducts and surfactants | UNION OIL COMPANY OF CALIFORNIA (US) | 1994-12-20 | — | — | US | claimed |
| US-5354563-A | Water dispersion containing ultrafine particles of organic compounds | RESEARCH DEVELOPMENT CORP. OF JAPAN (JP) | 1994-10-11 | — | — | US | claimed |
| US-5288692-A | Systemic herbicides and methods of use | UNION OIL COMPANY OF CALIFORNIA (US) | 1994-02-22 | — | — | US | claimed |
| EP-0209403-B1 | PROCESS FOR PREPARING ULTRAFINE PARTICLES OF ORGANIC COMPOUNDS | Research Development Corporation of Japan (JP) | 1991-10-23 | — | — | EP | claimed |
| US-4913865-A | Process for preparing ultrafine particles of organic compounds | RESEARCH DEVELOPMENT CORP OF JAPAN (JP) | 1990-04-03 | — | — | US | claimed |
| US-4805340-A | Humane glue trap for rats, mice and other vermin having carbomal in the bait | TAMBY CHEMICAL CORP. (US) | 1989-02-21 | — | — | US | claimed |
| EP-0209403-A2 | Process for preparing ultrafine particles of organic compounds | Research Development Corporation of Japan (JP) | 1987-01-21 | — | — | EP | claimed |
| US-4466953-A | Polymeric diffusion matrix | KEY PHARMACEUTICALS, INC. (US) | 1984-08-21 | — | — | US | claimed |
| US-3960757-A | HYDROPHOBIC | TOYO JOZO CO., LTD. (JA) | 1976-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273600-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SLC1A2, SLC6A5, SLC1A1 | CRBN 2865/4885HTT 250/4885RECQL 2022/4885 |
| US-10226442-B2 | Lithium salts of N-substituted glycine compounds and uses thereof | SLC1A2, SLC6A5, SLC1A1 | CRBN 2865/4885HTT 250/4885RECQL 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.